Johnson & Johnson
JNJ (NYSE)
Johnson & Johnson stands out as a healthcare leader, appealing to investors looking for stability and reliable income through its consistent dividends. With a low volatility profile and a strong balance sheet, it has delivered impressive returns of 47.51% over the past year and 57.95% over five years. Analysts have a favorable outlook, with a median 12-month price target of $220.00, highlighting its resilience in recessionary environments.
Pros:
- Low volatility
- Strong balance sheet
Cons:
- Recent separation of Consumer Health business
- Exposure to regulatory risks
Johnson & Johnson (JNJ) may be suitable for conservative investors seeking a blend of stability and income, given its solid dividend yield and low volatility profile. With impressive historical returns and a strong balance sheet, it represents a potentially reliable investment in the healthcare sector, particularly for those looking to mitigate risk during economic uncertainties.